- Home
- CCEL vs BCAB Comparison
CCEL vs BCAB Comparison
Compare CCEL & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- BCAB
- Stock Information
- Founded
- CCEL 1989
- BCAB 2007
- Country
- CCEL United States
- BCAB United States
- Employees
- CCEL N/A
- BCAB N/A
- Industry
- CCEL Managed Health Care
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- CCEL Health Care
- BCAB Health Care
- Exchange
- CCEL Nasdaq
- BCAB Nasdaq
- Market Cap
- CCEL 34.8M
- BCAB 31.5M
- IPO Year
- CCEL 1997
- BCAB 2020
- Fundamental
- Price
- CCEL $4.55
- BCAB $0.83
- Analyst Decision
- CCEL Strong Buy
- BCAB Hold
- Analyst Count
- CCEL 1
- BCAB 3
- Target Price
- CCEL $8.50
- BCAB $1.00
- AVG Volume (30 Days)
- CCEL 10.6K
- BCAB 1.2M
- Earning Date
- CCEL 10-15-2025
- BCAB 11-06-2025
- Dividend Yield
- CCEL 13.19%
- BCAB N/A
- EPS Growth
- CCEL N/A
- BCAB N/A
- EPS
- CCEL N/A
- BCAB N/A
- Revenue
- CCEL $31,747,500.00
- BCAB $11,000,000.00
- Revenue This Year
- CCEL $1.75
- BCAB N/A
- Revenue Next Year
- CCEL N/A
- BCAB N/A
- P/E Ratio
- CCEL N/A
- BCAB N/A
- Revenue Growth
- CCEL N/A
- BCAB N/A
- 52 Week Low
- CCEL $4.09
- BCAB $0.24
- 52 Week High
- CCEL $9.43
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- CCEL 47.89
- BCAB 55.19
- Support Level
- CCEL $4.35
- BCAB $0.66
- Resistance Level
- CCEL $4.60
- BCAB $1.06
- Average True Range (ATR)
- CCEL 0.13
- BCAB 0.13
- MACD
- CCEL -0.00
- BCAB -0.01
- Stochastic Oscillator
- CCEL 54.26
- BCAB 41.91
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.